The American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and Asociación Latinoamericana de Tórax have issued an update to their joint guidelines for the diagnosis and management

Diane Blum, MSW, FASCO, served as executive director of CancerCare and chief executive officer of the Lymphoma Research Foundation. Originally trained as a social worker, she worked at Dana Farber

Pulmonary fibrosis (PF) is a disease of the respiratory system caused by scarring (fibrosis) in the lungs, which makes it harder for patients to breathe. Based on the underlying cause of the scarring, PF

Nuformix has discovered novel forms of an undisclosed marketed oncology drug that has significant sales (more than £1 billion per annum in 2020) and is showing further growth We filed

Pulmonary fibrosis is a group of serious lung diseases that affect the respiratory system. Pulmonary fibrosis scars and thickens lung tissue. It impacts the connecting tissue in the lung and the

Nuformix said that it has published an international patent for its NXP004 asset, which could be used to treat a variety of illnesses. The UK pharmaceutical company said that NXP004

Idiopathic pulmonary fibrosis (IPF) is a serious chronic (long term) disease that affects the tissue surrounding the air sacs, or alveoli, in your lungs. This condition develops when that lung

NXP002 is our lead asset and a potential novel inhaled treatment for idiopathic pulmonary fibrosis Repurposed new form of the drug tranilast, to be delivered in an inhaled formulation. Tranilast